Cargando…
The Impact of Different Antihypertensive Drugs on Cardiovascular Risk in Isolated Systolic Hypertension with Type 2 Diabetes Patients
Backgrounds: Angiotensin receptor blockers (ARB), angiotensin converting enzyme inhibitor (ACEI), calcium channel blocker (CCB) and thiazide diuretics (TD) are common antihypertensive drugs for diabetes patients with hypertension. The purpose of this study was to compare the cardiovascular risks of...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655533/ https://www.ncbi.nlm.nih.gov/pubmed/36362714 http://dx.doi.org/10.3390/jcm11216486 |
_version_ | 1784829209302007808 |
---|---|
author | Gao, Ming Lin, Wenrui Ma, Tianqi Luo, Yi Xie, Hejian Cheng, Xunjie Bai, Yongping |
author_facet | Gao, Ming Lin, Wenrui Ma, Tianqi Luo, Yi Xie, Hejian Cheng, Xunjie Bai, Yongping |
author_sort | Gao, Ming |
collection | PubMed |
description | Backgrounds: Angiotensin receptor blockers (ARB), angiotensin converting enzyme inhibitor (ACEI), calcium channel blocker (CCB) and thiazide diuretics (TD) are common antihypertensive drugs for diabetes patients with hypertension. The purpose of this study was to compare the cardiovascular risks of these drugs in patients with isolated systolic hypertension (ISH) and type 2 diabetes mellitus (T2DM). Methods: We used Action to Control Cardiovascular Risk in Diabetes trial data to explore the relationship between antihypertensive drugs and cardiovascular risks in ISH with T2DM patients by performing propensity score matching, Kaplan–Meier survival analyses and Cox proportional regression. Results: The cumulative incidence rates of primary outcomes (PO, including cardiovascular mortality, non-fatal myocardial infarction and non-fatal stroke) in the ARB use group were significantly lower than those without (hazard ratio (HR) 0.53; 95% confidence interval (CI) 0.34–0.83; p = 0.006). However, for ACEI, CCB and TD, they were negligible (ACEI: p = 0.209; CCB: p = 0.245; TD: p = 0.438). ARB decreased cardiovascular mortality (CM) in PO rather than non-fatal myocardial infarction (NMI) and non-fatal stroke (NST) (CM: HR 0.32; 95%CI 0.18–0.90; p = 0.004; NMI: p = 0.692; NST: p = 0.933). Conclusion: ARB may alleviate the cardiovascular risks in ISH with T2DM patients, but ACEI, CCB, and TD did not. |
format | Online Article Text |
id | pubmed-9655533 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96555332022-11-15 The Impact of Different Antihypertensive Drugs on Cardiovascular Risk in Isolated Systolic Hypertension with Type 2 Diabetes Patients Gao, Ming Lin, Wenrui Ma, Tianqi Luo, Yi Xie, Hejian Cheng, Xunjie Bai, Yongping J Clin Med Article Backgrounds: Angiotensin receptor blockers (ARB), angiotensin converting enzyme inhibitor (ACEI), calcium channel blocker (CCB) and thiazide diuretics (TD) are common antihypertensive drugs for diabetes patients with hypertension. The purpose of this study was to compare the cardiovascular risks of these drugs in patients with isolated systolic hypertension (ISH) and type 2 diabetes mellitus (T2DM). Methods: We used Action to Control Cardiovascular Risk in Diabetes trial data to explore the relationship between antihypertensive drugs and cardiovascular risks in ISH with T2DM patients by performing propensity score matching, Kaplan–Meier survival analyses and Cox proportional regression. Results: The cumulative incidence rates of primary outcomes (PO, including cardiovascular mortality, non-fatal myocardial infarction and non-fatal stroke) in the ARB use group were significantly lower than those without (hazard ratio (HR) 0.53; 95% confidence interval (CI) 0.34–0.83; p = 0.006). However, for ACEI, CCB and TD, they were negligible (ACEI: p = 0.209; CCB: p = 0.245; TD: p = 0.438). ARB decreased cardiovascular mortality (CM) in PO rather than non-fatal myocardial infarction (NMI) and non-fatal stroke (NST) (CM: HR 0.32; 95%CI 0.18–0.90; p = 0.004; NMI: p = 0.692; NST: p = 0.933). Conclusion: ARB may alleviate the cardiovascular risks in ISH with T2DM patients, but ACEI, CCB, and TD did not. MDPI 2022-11-01 /pmc/articles/PMC9655533/ /pubmed/36362714 http://dx.doi.org/10.3390/jcm11216486 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gao, Ming Lin, Wenrui Ma, Tianqi Luo, Yi Xie, Hejian Cheng, Xunjie Bai, Yongping The Impact of Different Antihypertensive Drugs on Cardiovascular Risk in Isolated Systolic Hypertension with Type 2 Diabetes Patients |
title | The Impact of Different Antihypertensive Drugs on Cardiovascular Risk in Isolated Systolic Hypertension with Type 2 Diabetes Patients |
title_full | The Impact of Different Antihypertensive Drugs on Cardiovascular Risk in Isolated Systolic Hypertension with Type 2 Diabetes Patients |
title_fullStr | The Impact of Different Antihypertensive Drugs on Cardiovascular Risk in Isolated Systolic Hypertension with Type 2 Diabetes Patients |
title_full_unstemmed | The Impact of Different Antihypertensive Drugs on Cardiovascular Risk in Isolated Systolic Hypertension with Type 2 Diabetes Patients |
title_short | The Impact of Different Antihypertensive Drugs on Cardiovascular Risk in Isolated Systolic Hypertension with Type 2 Diabetes Patients |
title_sort | impact of different antihypertensive drugs on cardiovascular risk in isolated systolic hypertension with type 2 diabetes patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655533/ https://www.ncbi.nlm.nih.gov/pubmed/36362714 http://dx.doi.org/10.3390/jcm11216486 |
work_keys_str_mv | AT gaoming theimpactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients AT linwenrui theimpactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients AT matianqi theimpactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients AT luoyi theimpactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients AT xiehejian theimpactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients AT chengxunjie theimpactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients AT baiyongping theimpactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients AT gaoming impactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients AT linwenrui impactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients AT matianqi impactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients AT luoyi impactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients AT xiehejian impactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients AT chengxunjie impactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients AT baiyongping impactofdifferentantihypertensivedrugsoncardiovascularriskinisolatedsystolichypertensionwithtype2diabetespatients |